Molecular mechanism by which pioglitazone preserves pancreatic β-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARγ agonist

被引:55
作者
Kanda, Yukiko [1 ]
Shimoda, Masashi [1 ]
Hamamoto, Sumiko [1 ]
Tawaramoto, Kazuhito [1 ]
Kawasaki, Fumiko [1 ]
Hashiramoto, Mitsuru [1 ]
Nakashima, Koji [1 ]
Matsuki, Michihiro [1 ]
Kaku, Kohei [1 ]
机构
[1] Kawasaki Med Sch, Diabet & Endocrine Div, Kurashiki, Okayama, Japan
来源
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 2010年 / 298卷 / 02期
基金
日本学术振兴会;
关键词
beta-cell dysfunction; pioglitazone; oxidative stress; cell proliferation; cell apoptosis; ACTIVATED-RECEPTOR-GAMMA; INSULIN-RESISTANCE; OXIDATIVE STRESS; SECRETORY FUNCTION; GLUCOSE; ROSIGLITAZONE; PREVENTION; APOPTOSIS; MASS; TROGLITAZONE;
D O I
10.1152/ajpendo.00388.2009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Kanda Y, Shimoda M, Hamamoto S, Tawaramoto K, Kawasaki F, Hashiramoto M, Nakashima K, Matsuki M, Kaku K. Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPAR gamma agonist. Am J Physiol Endocrinol Metab 298: E278-E286, 2010. First published November 17, 2009; doi:10.1152/ajpendo.00388.2009.-Pioglitazone preserves pancreatic beta-cell morphology and function in diabetic animal models. In this study, we investigated the molecular mechanisms by which pioglitazone protects beta-cells in diabetic db/db mice. In addition to the morphological analysis of the islets, gene expression profiles of the pancreatic islet were analyzed using laser capture microdissection and were compared with real-time RT-PCR of db/db and nondiabetic m/m mice treated with or without pioglitazone for 2 wk or 2 days. Pioglitazone treatment (2 wk) ameliorated dysmetabolism, increased islet insulin content, restored glucose-stimulated insulin secretion, and preserved beta-cell mass in db/db mice but had no significant effects in m/m mice. Pioglitazone upregulated genes that promote cell differentiation/proliferation in diabetic and nondiabetic mice. In db/db mice, pioglitazone downregulated the apoptosis-promoting caspase-activated DNase gene and upregulated anti-apoptosis-related genes. The above-mentioned effects of pioglitazone treatment were also observed after 2 days of treatment. By contrast, the oxidative stress-promoting NADPH oxidase gene was downregulated, and antioxidative stress-related genes were upregulated, in db/db mice treated with pioglitazone for 2 wk, rather than 2 days. Morphometric results for proliferative cell number antigen and 4-hydroxy-2-noneal modified protein were consistent with the results of gene expression analysis. The present results strongly suggest that pioglitazone preserves beta-cell mass in diabetic mice mostly by two ways; directly, by acceleration of cell differentiation/proliferation and suppression of apoptosis (acute effect); and indirectly, by deceleration of oxidative stress because of amelioration of the underlying metabolic disorder (chronic effect).
引用
收藏
页码:E278 / E286
页数:9
相关论文
共 40 条
  • [1] TRIPOD (TRoglitazone in the Prevention of Diabetes): A randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus
    Azen, SP
    Peters, RK
    Berkowitz, K
    Kjos, S
    Xiang, A
    Buchanan, TA
    [J]. CONTROLLED CLINICAL TRIALS, 1998, 19 (02): : 217 - 231
  • [2] Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women
    Buchanan, TA
    Xiang, AH
    Peters, RK
    Kjos, SL
    Marroquin, A
    Goico, J
    Ochoa, C
    Tan, S
    Berkowitz, K
    Hodis, HN
    Azen, SP
    [J]. DIABETES, 2002, 51 (09) : 2796 - 2803
  • [3] The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats
    Choi, Sung Hee
    Zhao, Zheng Shan
    Lee, Yong Jik
    Kim, Soo Kyung
    Kim, Dae Jung
    Ahn, Chul Woo
    Lim, Sung Kil
    Lee, Hyun Chul
    Cha, Bong Soo
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2007, 23 (05) : 411 - 418
  • [4] PATHOGENESIS OF NIDDM - A BALANCED OVERVIEW
    DEFRONZO, RA
    BONADONNA, RC
    FERRANNINI, E
    [J]. DIABETES CARE, 1992, 15 (03) : 318 - 368
  • [5] Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes
    Diani, AR
    Sawada, G
    Wyse, B
    Murray, FT
    Khan, M
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 286 (01): : E116 - E122
  • [6] Mechanisms of β-cell death in type 2 diabetes
    Donath, MY
    Ehses, JA
    Maedler, K
    Schumann, DM
    Ellingsgaard, H
    Eppler, E
    Reinecke, M
    [J]. DIABETES, 2005, 54 : S108 - S113
  • [7] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
    Dormandy, JA
    Charbonnel, B
    Eckland, DJA
    Erdmann, E
    Massi-Benedetti, M
    Kmoules, IK
    Skene, AM
    Tan, MH
    Lefébvre, PJ
    Murray, GD
    Standl, E
    Wilcox, RG
    Wlhelmsen, L
    Betteridge, J
    Birkeland, K
    Golay, A
    Heine, RJ
    Korányi, L
    Laakso, M
    Mokán, M
    Norkus, A
    Pirags, V
    Podar, T
    Scheen, A
    Scherbaum, W
    Schernthaner, G
    Schmitz, O
    Skrha, J
    Smith, U
    Taton, J
    [J]. LANCET, 2005, 366 (9493) : 1279 - 1289
  • [8] Expression of peroxisome proliferator-activated receptor γ (PPARγ) in normal human pancreatic islet cells
    Dubois, M
    Pattou, F
    Kerr-Conte, J
    Gmyr, V
    Vandewalle, B
    Desreumaux, P
    Auwerx, J
    Schoonjans, K
    Lefebvre, J
    [J]. DIABETOLOGIA, 2000, 43 (09) : 1165 - 1169
  • [9] Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance
    Durbin, RJ
    [J]. DIABETES OBESITY & METABOLISM, 2004, 6 (04) : 280 - 285
  • [10] Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction?
    Evans, JL
    Goldfine, ID
    Maddux, BA
    Grodsky, GM
    [J]. DIABETES, 2003, 52 (01) : 1 - 8